Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...

Sickle cell anemia (HbSS) is the homozygous dominant variant and the most common and severe form of the disease. Whereas patients who only inherited one gene encoding for abnormal HbS and a different ...

NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...

Pain related to sickle cell disease (SCD) increases during menstruation, as do emergency department (ED) visits and hospitalizations, for many women and girls—according to a new, nationwide study led ...

LentiGlobin gene therapy for sickle cell disease (bb1111) is an investigational treatment being studied as a potential treatment for SCD. bluebird bio’s clinical development program for LentiGlobin ...

Opportunities in the Sickle Cell Disease market include advancing gene-editing therapies like EDIT-301, expanding VOC-reducing treatments such as inclacumab, and exploring novel drug candidates like ...

The specific carbohydrate diet (SCD) is popular among people with inflammatory bowel disease (IBD). It focuses on simple carbohydrates and unprocessed foods. Haas and Gottschall claimed the diet could ...

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...